All In Biotech

Drug Trial Radar · NCT04139122

Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease

A Randomized, Double-Masked, Single-Center, Placebo-Controlled Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of SJP-0132 in Subjects With Dry Eye Disease

Last checked: Nov 19, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

89

Actual

Start

Oct 5, 2019

Primary completion

Mar 3, 2020

Study completion Mar 3, 2020

Sponsor

Lead sponsor
Senju Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first study in humans to evaluate the effectiveness of SJP-0132 in the treatment of dry eye disease. This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of single- and multiple-dose regimens of SJP-0132 in subjects with dry eye disease

Conditions

  • Dry Eye Disease
  • Dry Eye Syndrome

Interventions

  • SJP-0132Drug

    SJP-0132 is administered as an eye drop

  • PlaceboDrug

    Placebo is administered as an eye drop

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events by Severity in Each CohortTime frame: Day 2 for cohort 1-4, Day 29 for cohort 5-6
  2. Number of Subjects With Abnormal Changes in Laboratory Parameters, Vital Signs, and/or Physical and Ophthalmologic Observations in Each CohortTime frame: Day 2 for cohort 1-4, Day 29 for cohort 5-6
  3. Maximum Plasma Concentration (Cmax)Time frame: Day 1
  4. Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC0-last)Time frame: Day 1
  5. Accumulation Ratio (Rac) After Multiple DosingTime frame: Day 2, 4, 8
  6. Change From Baseline in Eye Dryness Symptom (VAS) at 4hour on Day 29Time frame: Day 29
  7. Change From Baseline in Corneal Fluorescein Staining (CFS) Score at the Central Zone on Day 29Time frame: Day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Senju Investigational Site

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.